The global liquid biopsy market is predicted to surpass US$ 11 Billion by 2030. The advantages of liquid biopsy over solid tumor biopsy, rising prevalence of cancer, increasing preference for non-invasive procedures, growing public and private funding to support research activities in the field of liquid biopsy and favorable government initiatives, are some of the factors expected to propel the growth of liquid biopsy market in the coming years. Some of the key factors inhibiting the growth of liquid biopsy market includes, clinical utility challenges, lack of sensitivity and specificity of liquid biopsy tests and unclear reimbursement & regulation scenario.
Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. Liquid biopsy is a non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. The abilities of liquid biopsy like, easy and minimal invasiveness, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients.
Impact of COVID-19 on Global Liquid Biopsy Market
The COVID-19 outbreak has become a global stress test. As the number of people infected with the virus continues to rise around the world, uncertainties about global economic growth increases. The COVID-19 disease has infected around 532 Million people worldwide. Globally the death toll has reached 6,311,594 according to the latest statistics from the Worldometers (as of May 31, 2022). The number is still growing, and the duration of the pandemic is still difficult to predict. The reactions to the COVID-19 pandemic and its effects on societies and economies around the world cannot be understated. The COVID-19 global pandemic has restricted the growth rate of the liquid biopsy market to some extent during 2020-2021. However, many countries have taken strict measures to combat the coronavirus, such as mass vaccination program, social distancing, use of masks, etc. Hence, we expect that the physicians/surgeons will see an increase in influx of patients, hence driving the liquid biopsy market growth.
Recent Developments
- In March 2022, the Japanese Ministry of Health, Labour and Welfare granted regulatory approval of Guardant360 CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumors.
- In February 2022, Labcorp, a leading global life sciences company, closed its acquisition of Personal Genome Diagnostics Inc., a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
- In July 2021, Biocept, Inc. was awarded a South Korean Patent for its Primer-Switch technology, which detects rare mutations in circulating tumor DNA (ctDNA) using real-time PCR and associated analysis methods.
- In March 2021, Lucence announced a partnership with Waseda University in Japan to develop a novel high-speed liquid biopsy laser-based imaging platform for early cancer detection.
- In February 2021, Guardant Health, Inc. announced the availability of Guardant Reveal, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw.
Global Liquid Biopsy Market & Forecast - by Circulating Biomarker
- Based on circulating biomarkers, in 2021, the circulating tumor cells (CTCs) segment captured largest share of the liquid biopsy market.
- The circulating tumor DNA (ctDNA) is the 2nd largest segment of the liquid biopsy market.
- The extracellular vesicles (EVs) segment is the fastest growing segment during the forecast period.
Global Liquid Biopsy Market & Forecast - by Products
- On the basis of product, the Kits and Consumables segment is expected to account for largest share of the liquid biopsy market.
- The instruments segment is likely to witness highest growth in the global liquid biopsy market.
- The services segment captured least share of the liquid biopsy market.
Global Liquid Biopsy Market & Forecast - by Application
- The global liquid biopsy market, by application, is being dominated by oncology application.
- Lung cancer and breast cancer accounts for largest share of the liquid biopsy oncology market.
- The non-cancer application segment is expected to be the fastest-growing segment in the market during the forecast period.
Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application
- On the basis of clinical application, the therapy selection segment is expected to account for largest share of the liquid biopsy market throughout the forecast period.
- Treatment monitoring captured second highest share of the liquid biopsy market in 2021, being followed by the early cancer screening application.
- Recurrence monitoring captured least share of the liquid biopsy market.
Global Liquid Biopsy Market & Forecast - by End User
- In 2021, Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market.
- Hospital and Physician laboratories occupied second highest share of the liquid biopsy market in 2021, being followed by Academic and Research Centers.
Global Liquid Biopsy Market & Forecast - by Sample Type
- Blood is the most widely used sample type and is expected to remain the largest market during the forecasting period as well.
- The urine sample segment is anticipated to witness noticeable growth throughout the forecast period.
Liquid Biopsy Market & Forecast - Regional Analysis
- North America accounted for largest share of the global liquid biopsy market in 2021.
- In 2021, Europe captured second largest share of the global liquid biopsy market.
- In Europe, Germany and France are the leading market for liquid biopsy.
- Asia pacific is the fastest growing market for liquid biopsy.
- In Asia Pacific, Japan and China are the leading market for liquid biopsy.
- Latin America is the fourth largest market for liquid biopsy, being followed by Middle East & Africa.
iGATE RESEARCH, report titled "Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End Users, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Impact of COVID-19, Initiatives, Funding, Major Deals, Company Profiles and Recent Developments - Global Forecast to 2030" provides a comprehensive assessment of the fast-evolving, high-growth Global Liquid Biopsy Market.
This 611 Page report with 118 Figures and 7 Tables has been analyzed from 16 viewpoints:
1. Global Liquid Biopsy Market & Forecast (2016 - 2030)
2. Impact of COVID-19 on Global Liquid Biopsy Market
3. Global Liquid Biopsy Market Share & Forecast (2016 - 2030)
4. Global Liquid Biopsy Market & Forecast - by Circulating Biomarker (2016 - 2030)
5. Global Liquid Biopsy Market & Forecast - by Product (2016 - 2030)
6. Global Liquid Biopsy Market & Forecast - by Application (2016 - 2030)
7. Global Liquid Biopsy Oncology Market & Forecast - By Cancer Types (2016 - 2030)
8. Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application (2016 - 2030)
9. Global Liquid Biopsy Market & Forecast - by End User (2016 - 2030)
10. Global Liquid Biopsy Market & Forecast - by Sample Type (2016 - 2030)
11. Liquid Biopsy Market & Forecast - Regional Analysis (2016 - 2030)
12. Liquid Biopsy Market Share & Forecast - Geographical Analysis (2016 - 2030)
13. Liquid Biopsy Initiatives
14. Liquid Biopsy Companies Financing Details
15. 35 Company Profiles - Recent Developments / Initiatives, Major Deals
16. Global Liquid Biopsy Market - Driving Factors & Challenges
Global Liquid Biopsy Market & Forecast - by Circulating Biomarker
1. Circulating Tumor Cells (CTCs)
2. Circulating Tumor DNA (ctDNA)
3. Cell-Free DNA (cfDNA)
4. Extracellular Vesicles (EVs)
5. Other Circulating Biomarkers
Global Liquid Biopsy Market & Forecast - by Product
1. Kits and Consumables
2. Instruments
3. Services
Global Liquid Biopsy Market & Forecast - by Application
1. Oncology Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Leukaemia
- Others
2. Non-Cancer Application
Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application
1. Therapy Selection
2. Treatment Monitoring
3. Early Cancer Screening
4. Recurrence Monitoring
Global Liquid Biopsy Market & Forecast - by End User
1. Reference Laboratories
2. Hospitals and Physician Laboratories
3. Academic and Research Centers
4. Other End Users
Global Liquid Biopsy Market & Forecast - by Sample Type
1. Blood Sample
2. Urine Sample
3. Other Fluids Sample
Liquid Biopsy Market & Forecast - Regional Analysis
1. North America
2. Asia Pacific
- South Korea
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
3. Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
4. Middle East & Africa
- UAE
- Saudi Arabia
- Egypt
- Rest of Middle East & Africa
5. Latin America
Liquid Biopsy Market - Company Profiles, Recent Developments / Initiatives, Major Deals
1. Personal Genome Diagnostics
2. Guardant Health, Inc.
3. Pathway Genomics (Now OME CARE)
4. RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
5. Cardiff Oncology (Previously Trovagene, Inc.)
6. LungLife AI (Formerly Cynvenio Biosystems, Inc.)
7. Biocept, Inc.
8. ANGLE plc
9. MDxHealth
10. Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
11. Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
12. Foundation Medicine, Inc
13. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
14. Genomic Health (Now Part of Exact Sciences Corp)
15. Myriad Genetics, Inc
16. Thermo Fisher Scientific, Inc
17. QIAGEN NV
18. Bio-Rad Laboratories, Inc
19. Menarini-Silicon Biosystems
20. GRAIL
21. NeoGenomics, Inc.
22. DiaCarta, Inc.
23. OncoCell MDx (Now Immunis.AI)
24. C2i Genomics
25. Biodesix
26. Freenome
27. Inivata
28. CellMax Life
29. Rarecyte Inc.
30. Saga Diagnostics
31. Thrive Earlier Detection Corp. (Acquired by Exact Sciences Corp.)
32. Lucence Diagnostics Pte Ltd
33. Karius, Inc.
34. Clinical Genomics Technologies Pty Ltd (CG)
35. Elypta
Data Sources
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Research Methodologies
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.
Table of Contents
1. Executive Summary
2. Impact of COVID-19 on Global Liquid Biopsy Market
3. Global Liquid Biopsy Market & Forecast (2016 - 2030)
4. Global Liquid Biopsy Market Share & Forecast (2016 - 2030)
- 4.1 Global Liquid Biopsy Market Share & Forecast - by Circulating Biomarker
- 4.2 Global Liquid Biopsy Market Share & Forecast - by Product
- 4.3 Global Liquid Biopsy Market Share & Forecast - by Application
- 4.4 Global Liquid Biopsy Oncology Market Share & Forecast - by Clinical Application
- 4.5 Global Liquid Biopsy Oncology Market Share & Forecast - By Cancer Types
- 4.6 Global Liquid Biopsy Market Share & Forecast - by End User
- 4.7 Global Liquid Biopsy Market Share & Forecast - by Sample Type
- 4.8 Liquid Biopsy Market Share & Forecast - Regional Analysis
- 4.9 Liquid Biopsy Market Share & Forecast - Country Wise Analysis
5. Global Liquid Biopsy Market & Forecast - by Circulating Biomarker (2016 - 2030)
- 5.1 Global Liquid Biopsy - Circulating Tumor Cells (CTCs) Market & Forecast
- 5.2 Global Liquid Biopsy - Circulating Tumor DNA (ctDNA) Market & Forecast
- 5.3 Global Liquid Biopsy - Cell-Free DNA (cfDNA) Market & Forecast
- 5.4 Global Liquid Biopsy - Extracellular Vesicles (EVs) Market & Forecast
- 5.5 Global Liquid Biopsy - Other Circulating Biomarkers Market & Forecast
6. Global Liquid Biopsy Market & Forecast - by Product (2016 - 2030)
- 6.1 Global Liquid Biopsy - Kits and Consumables Market & Forecast
- 6.2 Global Liquid Biopsy - Instruments Market & Forecast
- 6.3 Global Liquid Biopsy - Services Market & Forecast
7. Global Liquid Biopsy Market & Forecast - by Application (2016 - 2030)
- 7.1 Global Liquid Biopsy - Oncology Application Market & Forecast
- 7.2 Global Liquid Biopsy Oncology Market & Forecast - By Cancer Types
- 7.2.1 Lung Cancer Liquid Biopsy Market & Forecast
- 7.2.2 Breast Cancer Liquid Biopsy Market & Forecast
- 7.2.3 Colorectal Cancer Liquid Biopsy Market & Forecast
- 7.2.4 Prostate Cancer Liquid Biopsy Market & Forecast
- 7.2.5 Gastrointestinal Cancer Liquid Biopsy Market & Forecast
- 7.2.6 Leukaemia Liquid Biopsy Market & Forecast
- 7.2.7 Others Liquid Biopsy Market & Forecast
- 7.3 Global Liquid Biopsy - Non-Cancer Application Market & Forecast
8. Global Liquid Biopsy Oncology Market & Forecast - by Clinical Application (2016 - 2030)
- 8.1 Global Liquid Biopsy Oncology Application - Therapy Selection Market & Forecast
- 8.2 Global Liquid Biopsy Oncology Application - Treatment Monitoring Market & Forecast
- 8.3 Global Liquid Biopsy Oncology Application - Early Cancer Screening Market & Forecast
- 8.4 Global Liquid Biopsy Oncology Application - Recurrence Monitoring Market & Forecast
9. Global Liquid Biopsy Market & Forecast - by End User (2016 - 2030)
- 9.1 Global Liquid Biopsy - Reference Laboratories Market & Forecast
- 9.2 Global Liquid Biopsy - Hospitals and Physician Laboratories Market & Forecast
- 9.3 Global Liquid Biopsy - Academic and Research Centers Market & Forecast
- 9.4 Global Liquid Biopsy - Other End Users Market & Forecast
10. Global Liquid Biopsy Market & Forecast - by Sample Type (2016 - 2030)
- 10.1 Global Liquid Biopsy - Blood Sample Market & Forecast
- 10.2 Global Liquid Biopsy - Urine Sample Market & Forecast
- 10.3 Global Liquid Biopsy - Other Fluids Sample Market & Forecast
11. Liquid Biopsy Market & Forecast - Regional Analysis (2016 - 2030)
- 11.1 North America Liquid Biopsy Market & Forecast
- 11.2 Asia Pacific Liquid Biopsy Market & Forecast
- 11.3 Europe Liquid Biopsy Market & Forecast
- 11.4 Latin America Liquid Biopsy Market & Forecast
- 11.5 Middle East & Africa Liquid Biopsy Market & Forecast
12. Liquid Biopsy Market Share & Forecast - Geographical Analysis (2016 - 2030)
- 12.1 North America Liquid Biopsy Market & Forecast
- 12.1.1 United States Liquid Biopsy Market & Forecast
- 12.1.2 Canada Liquid Biopsy Market & Forecast
- 12.2 Asia Pacific Liquid Biopsy Market & Forecast
- 12.2.1 South Korea Liquid Biopsy Market & Forecast
- 12.2.2 Japan Liquid Biopsy Market & Forecast
- 12.2.3 China Liquid Biopsy Market & Forecast
- 12.2.4 India Liquid Biopsy Market & Forecast
- 12.2.5 Australia Liquid Biopsy Market & Forecast
- 12.2.6 Rest of Asia Pacific Liquid Biopsy Market & Forecast
- 12.3 Europe Liquid Biopsy Market & Forecast
- 12.3.1 Germany Liquid Biopsy Market & Forecast
- 12.3.2 France Liquid Biopsy Market & Forecast
- 12.3.3 United Kingdom Liquid Biopsy Market & Forecast
- 12.3.4 Italy Liquid Biopsy Market & Forecast
- 12.3.5 Spain Liquid Biopsy Market & Forecast
- 12.3.6 Rest of Europe Liquid Biopsy Market & Forecast
- 12.4 Middle East & Africa Liquid Biopsy Market & Forecast
- 12.4.1 UAE Liquid Biopsy Market & Forecast
- 12.4.2 Saudi Arabia Liquid Biopsy Market & Forecast
- 12.4.3 Egypt Liquid Biopsy Market & Forecast
- 12.4.4 Rest of Middle East & Africa Liquid Biopsy Market & Forecast
- 12.5 Latin America Liquid Biopsy Market & Forecast
13. Liquid Biopsy Initiatives
14. Liquid Biopsy Companies Financing Details
15. Company Profiles
- 15.1 Personal Genome Diagnostics (Acquired by Labcorp)
- 15.1.1 Company Overview
- 15.1.2 Recent Developments / Initiatives
- 15.2 Guardant Health, Inc.
- 15.2.1 Company Overview
- 15.2.2 Recent Developments / Initiatives
- 15.3 Pathway Genomics (Now OME CARE)
- 15.3.1 Company Overview
- 15.3.2 Recent Developments / Initiatives
- 15.4 RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)
- 15.4.1 Company Overview
- 15.4.2 Recent Developments / Initiatives
- 15.5 Cardiff Oncology (Previously Trovagene, Inc.)
- 15.5.1 Company Overview
- 15.5.2 Recent Developments / Initiatives
- 15.6 LungLife AI (Formerly Cynvenio Biosystems, Inc.)
- 15.6.1 Company Overview
- 15.6.2 Recent Developments / Initiatives
- 15.7 Biocept, Inc.
- 15.7.1 Company Overview
- 15.7.2 Recent Developments / Initiatives
- 15.8 ANGLE plc
- 15.8.1 Company Overview
- 15.8.2 Recent Developments / Initiatives
- 15.9 MDxHealth
- 15.9.1 Company Overview
- 15.9.2 Recent Developments / Initiatives
- 15.10 Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)
- 15.10.1 Company Overview
- 15.10.2 Recent Developments / Initiatives
- 15.11 Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)
- 15.11.1 Company Overview
- 15.11.2 Recent Developments / Initiatives
- 15.12 Foundation Medicine, Inc.
- 15.12.1 Company Overview
- 15.12.2 Recent Developments / Initiatives
- 15.13 Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)
- 15.13.1 Company Overview
- 15.13.2 Recent Developments / Initiatives
- 15.14 Genomic Health (Now Part of Exact Sciences Corp)
- 15.14.1 Company Overview
- 15.14.2 Recent Developments / Initiatives
- 15.15 Myriad Genetics, Inc.
- 15.15.1 Company Overview
- 15.15.2 Recent Developments / Initiatives
- 15.16 Thermo Fisher Scientific, Inc.
- 15.16.1 Company Overview
- 15.16.2 Recent Developments / Initiatives
- 15.17 QIAGEN NV
- 15.17.1 Company Overview
- 15.17.2 Recent Developments / Initiatives
- 15.18 Bio-Rad Laboratories, Inc.
- 15.18.1 Company Overview
- 15.18.2 Recent Developments / Initiatives
- 15.19 Menarini-Silicon Biosystems
- 15.19.1 Company Overview
- 15.19.2 Recent Developments / Initiatives
- 15.20 GRAIL
- 15.20.1 Company Overview
- 15.20.2 Recent Developments / Initiatives
- 15.21 NeoGenomics, Inc.
- 15.21.1 Company Overview
- 15.21.2 Recent Developments / Initiatives
- 15.22 DiaCarta, Inc.
- 15.22.1 Company Overview
- 15.22.2 Recent Developments / Initiatives
- 15.23 OncoCell MDx (Now Immunis.AI)
- 15.23.1 Company Overview
- 15.23.2 Recent Developments / Initiatives
- 15.24 C2i Genomics
- 15.24.1 Company Overview
- 15.24.2 Recent Developments / Initiatives